Program Summary

Program Summary

The purpose of this funding opportunity announcement (FOA) is to invite applications for Clinical Centers (Hubs) in Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN).  SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, and hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). A Hub will typically be an academic center or tertiary referral center which will actively enroll patients into every clinical trial performed in SIREN, regardless of disease focus.  A Hub will additionally provide scientific leadership and administrative oversight to its multiple satellite sites ("Spokes").  Together the Hub and Spokes will provide access to a large and varying patient population for clinical trials. SIREN will implement a total of at least four large (>1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peer–reviewed projects which will be awarded under separate funding announcements.

Application Limits

Application Limits

Only one Hub application per institution

Additional Information

Deadlines

UIC Letter of Intent
March 28, 2016
UIC Internal Competition
TBD
Sponsor Letter of Intent
May 1, 2016
Sponsor Application
June 1, 2016

Letter of Intent

Letter of Intent

Letter of Intent (LOI) Form

 

Depending upon the number of LOIs submitted, OVCR might be required to facilitate an internal peer review process to select UIC’s submission(s) to this program.  White paper instructions will distributed to those who have submitted LOIs.

 

Please contact Tony Halford at RDS@uic.edu or 6-7036 with any questions.

 

If an authorized principal investigator is not listed above, please consider the limited competition still open. Contact RDS@uic.edu for further information.